Untitled

Ell count, HIV-RNA, concomitant medications, comorbidities, and plasma TFV CBR-5884 supplier trough concentrations.
Ell count, HIV-RNA, concomitant medications, comorbidities, and plasma TFV trough concentrations.Statistical analysisThe time from baseline to renal dysfunction was analyzed using the Kaplan-Meier method. Baseline characteristics were compared between patients with and without renal dysfunction using Mann-Whitney U tests or Fisher’s exact tests. Univariate analysis was conducted to reduce the list of potential variables associated with renal dysfunction. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27864321 The potential variables associated with renal dysfunction with p 0.1 in the univariate analysis were entered into correlation analyses. Statistical significance was defined as a two-sided p < 0.05. All analyses were performed using StatMate IV (ATMS Co. Ltd., Tokyo, Japan).Results Of the 12 patients who were enrolled, one patient was excluded due to a congenital solitary kidney. Patient characteristics are presented in Table 1. All of the study patients were men and had a relatively low body weight (median body weight, 56.1 kg). No patient had comorbidities such as hypertension, diabetes, or hepatitis C. The cART regimens PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27607577 included a protease inhibitor for 63.6 of the patients (n = 5, darunavir/ritonavir; n = 2, fosamprenavir/ritonavir) and an integrase strand transferinhibitor (raltegravir) for 36.4 of the patients. The median time to plasma TFV trough concentration measurements was 9 weeks after starting a TDF-containing cART regimen. For the seven patients (63.6 ) in whom renal dysfunction occurred, it occurred within 24 weeks from cART initiation. The cumulative incidence of renal dysfunction in these patients was 9.1, 27.3, 45.5, 54.5, and 63.6 at 4, 8, 12, 16?0, and 24?8 weeks, respectively. The changes in classified CKD stage after treatment in these patients were from stage 1 to 2, stage 1 to 3, and stage 2 to 3 in 3, 2, and two patients, respectively. Table 2 compares the baseline characteristics between patients with and without renal dysfunction. The rate of decrease in eGFR was significantly different between the 2 groups (p = 0.008). In patients with renal dysfunction, age and plasma TFV trough concentrations tended to be higher, and weight and BMI tended to be lower. Data regarding the 11 patients are given in Additional file 1. The rate of decrease in eGFR was not significantly correlated with age (Fig. 1a, Spearman correlation = 0.403, p = 0.203), but was significantly correlated with weight (Fig. 1b, Spearman correlation = -0.645, p = 0.041), BMI (Fig. 1c, Spearman correlation = -0.682, p = 0.031), and plasma TFV trough concentrations (Fig. 1d, Spearman correlation = 0.709, p = 0.025).Discussion We showed that higher plasma TFV trough concentrations tended to be associated with a decrease in eGFR after starting cART. In principle, ARVs are required for a person’s entire lifetime. Most of the NRTI class ofTable 2 Characteristics of patients with or without renal dysfunctionRenal dysfunction patients N=7 Age (years) a Body weight (kg) BMI (kg/m2) a BSA (m )2 a aNon-renal dysfunction patients N=4 29.5 (24.0?5.8) 60.8 (59.0?8.8) 21.3 (20.2?3.8) 1.70 (1.69?.79) 0.80 (0.78?.83) 90.4 (82.7?04.2) 11.7 (8.0?2.9) 204 (99?20) 5.33 (4.82?.92) 3 (75.0) 1 (25.0) 2 (50) 0 (0) 56.0 (50.5?0.5)p value 0.072 0.078 0.078 0.169 0.163 0.925 0.008 0.149 0.395 1.000 1.000 0.576 0.236 0.45.0 (38.0?2.0) 52.2 (49.4?2.9) 17.7 (17.2?0.9) 1.60 (1.57?.77) 0.70 (0.65?.80) 96.1 (85.9?02.9) 33.2 (24.3?8.2) 58 (36?33) 4.63 (4.52?.84) 4 (57.1) 3 (42.9) 2 (28.6) 3 (42.6) 88.0 (67.0?02.5)2 aSerum cre.

Leave a Reply